




REALISING THE FULL POTENTIAL OF BENEFIT-SHARING PROGRAMS FOR BIOLOGICS

A European Comparative Analysis of Implementation Challenges

Barcina Lacosta T ¹, Vulto AG ^{1,2}, Turcu-Stiolica A ³, Huys I ¹, Simoens S ¹

DEFINING THE SCOPE OF BENEFIT-SHARING PROGRAMS

WHAT?

Collaborative arrangements between stakeholders in healthcare

WHO?

HEALTHCARE PROVIDERS

Prescribers, nurses, pharmacists, managers

PAYERS

NHS, insurer groups

WHY?

To generate savings by incentivizing the use of ‘best-value’ biologics (BVB)

HOW?

- 1.Setting prescription objectives for BVB – encouraging HCPs to comply with the objectives
- 2.Generating/sharing savings with the stakeholders involved in the benefit-sharing initiatives
- 3.Establishing pathways for saving’s reinvestment that would allow quality of care improvements

OBJECTIVES

- > Categorize diverse designs of benefit-sharing programs
- > Identify implementation barriers and facilitators
- > Propose recommendations to realize the full potential of benefit-sharing programs

METHODOLOGY

- 1.Literature review: academic databases and grey literature repositories
- 2.Semi-structured interviews – Interview guide prepared according to the principles of the Consolidated Framework Implementation Research
 - > **N=16**; Included countries: UK, France, Germany, Ireland, Italy, the Netherlands, Poland, Portugal, Romania, Sweden

Contact - Teresa Barcina Lacosta; teresa.barcina@kuleuven.be

Authors affiliations - 1.Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Belgium; 2.Hospital pharmacy. Erasmus University Medical Center, Rotterdam, the Netherlands; 3.University of Medicine and Pharmacy of Craiova, Craiova, Romania



RESULTS - MAPPING BENEFIT-SHARING EXPERIENCES ACROSS EUROPE




2016

|

present

ACSS-NHS hospitals | Adalimumab, enoxaparin sodium, epoietin, etanercept, filgrastim, infliximab, rituximab, somatropin, trastuzumab
Prescribed/dispensed (hospitals)
Uptake objective(biosimilars) – 20% | 15-25% of savings remain at the hospital level



2018

|

2022

MoH-Hospitals | Adalimumab, etanercept, insulin glargine
Prescribed (hospitals)–dispensed (community pharmacies)
Uptake objective (biosimilars) – 80% in 2022
20-30% of savings remain at the hospital level



2019

|

present

HSE-Hospitals| Adalimumab, etanercept
Prescribed (hospitals)–dispensed (community pharmacies)
Uptake BVB- 80%
Clinical services receive 500€/ patient treated with a BVB | 3.6M€ savings reinvested in patient care



National-level initiatives



Benefit-sharing principles set nationally; conditions agreed locally



Benefit-sharing conditions set locally

LEARNINGS – UNLOCKING THE POTENTIAL OF BENEFIT-SHARING STRATEGIES

- > Benefit-sharing programs have the potential to align the goals/expectations of payers, healthcare professionals (HCPs) and patients regarding prescribing practices for biologics.
- > The establishment of clear objectives and clear criteria to redistribute the savings is encouraged and should happen prior to agreeing on a benefit-sharing program.
- > It is recommended to link the set-up of benefit-sharing initiatives with success indicators based on quality of care improvements (and not only on cost-savings). These indicators are to be set by HCPs and patient advocacy groups, according to patient’s needs.
- > It is recommended to increase transparency in the reporting of outcomes from benefit-sharing programs and to include patients in the communication strategy.